Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial.
Josep TaberneroPaulo M HoffLin ShenAtsushi OhtsuManish A ShahAsna SiddiquiSarah HeesonAstrid KiermaierHarrison MachariaEleonora RestucciaYoon-Koo KangPublished in: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2022)
JACOB did not meet its primary endpoint. Nonetheless, the study continues to demonstrate some, albeit limited, evidence of treatment activity and an acceptable safety profile for pertuzumab plus trastuzumab and chemotherapy in previously untreated HER2-positive metastatic gastric or gastroesophageal junction cancer after long-term follow-up. Trial registration NCT01774786; https://clinicaltrials.gov/ct2/show/NCT01774786 .
Keyphrases
- phase iii
- epidermal growth factor receptor
- papillary thyroid
- clinical trial
- metastatic breast cancer
- open label
- squamous cell carcinoma
- computed tomography
- study protocol
- magnetic resonance
- tyrosine kinase
- childhood cancer
- contrast enhanced
- placebo controlled
- combination therapy
- image quality
- smoking cessation
- rectal cancer
- chemotherapy induced